Collegium Pharmaceutical (COLL) Revenue & Revenue Breakdown
Collegium Pharmaceutical Revenue Highlights
Latest Revenue (Y)
$566.77M
Latest Revenue (Q)
$144.92M
Main Segment (Y)
Belbuca
Collegium Pharmaceutical Revenue by Period
Collegium Pharmaceutical Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $566.77M | 22.17% |
| 2022-12-31 | $463.93M | 67.56% |
| 2021-12-31 | $276.87M | -10.69% |
| 2020-12-31 | $310.02M | 4.49% |
| 2019-12-31 | $296.70M | 5.81% |
| 2018-12-31 | $280.41M | 884.73% |
| 2017-12-31 | $28.48M | 1564.29% |
| 2016-12-31 | $1.71M | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Collegium Pharmaceutical generated $566.77M in revenue during NA 2023, up 22.17% compared to the previous quarter, and up 202.12% compared to the same period a year ago.
Collegium Pharmaceutical Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $144.92M | -3.22% |
| 2023-12-31 | $149.75M | 9.54% |
| 2023-09-30 | $136.71M | 0.86% |
| 2023-06-30 | $135.55M | -6.37% |
| 2023-03-31 | $144.77M | 11.69% |
| 2022-12-31 | $129.62M | 2.05% |
| 2022-09-30 | $127.01M | 2.80% |
| 2022-06-30 | $123.55M | 47.52% |
| 2022-03-31 | $83.75M | 206.09% |
| 2021-12-31 | $27.36M | -65.30% |
| 2021-09-30 | $78.84M | -4.94% |
| 2021-06-30 | $82.94M | -5.45% |
| 2021-03-31 | $87.72M | 15.01% |
| 2020-12-31 | $76.27M | -3.67% |
| 2020-09-30 | $79.18M | 1.43% |
| 2020-06-30 | $78.06M | 2.02% |
| 2020-03-31 | $76.51M | 3.11% |
| 2019-12-31 | $74.20M | 1.73% |
| 2019-09-30 | $72.94M | -2.80% |
| 2019-06-30 | $75.04M | 0.70% |
| 2019-03-31 | $74.52M | 1.48% |
| 2018-12-31 | $73.43M | 4.63% |
| 2018-09-30 | $70.18M | -3.95% |
| 2018-06-30 | $73.06M | 14.61% |
| 2018-03-31 | $63.75M | 490.60% |
| 2017-12-31 | $10.79M | -9.67% |
| 2017-09-30 | $11.95M | 235.67% |
| 2017-06-30 | $3.56M | 63.90% |
| 2017-03-31 | $2.17M | 66.69% |
| 2016-12-31 | $1.30M | 219.36% |
| 2016-09-30 | $408.00K | 100.00% |
| 2016-06-30 | - | 100.00% |
| 2016-03-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2015-06-30 | - | 100.00% |
| 2015-03-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | 100.00% |
| 2014-06-30 | - | 100.00% |
| 2014-03-31 | - | - |
Collegium Pharmaceutical generated $144.92M in revenue during Q1 2024, up -3.22% compared to the previous quarter, and up 111.81% compared to the same period a year ago.
Collegium Pharmaceutical Revenue Breakdown
Collegium Pharmaceutical Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 | Dec 19 |
|---|---|---|---|---|---|
| Nucynta IR | $108.15M | $112.06M | $102.22M | - | - |
| Symproic | $16.50M | $12.27M | - | - | - |
| Xtampza ER | $177.37M | $138.80M | $103.71M | - | - |
| Belbuca | $182.09M | $126.46M | - | - | - |
| Nucynta ER | $82.65M | $72.42M | $70.94M | - | - |
| Other | - | $1.93M | - | - | - |
| Nucynta Products | - | - | $173.16M | - | - |
| Xtampza | - | - | - | $127.98M | $105.01M |
| Nucynta Er | - | - | - | $65.71M | $74.01M |
| Nucynta Ir | - | - | - | $116.32M | $117.68M |
| Nucynta | - | - | - | $182.03M | $191.69M |
Collegium Pharmaceutical's latest annual revenue breakdown by segment (product or service), as of Dec 23: Belbuca (32.13%), Xtampza ER (31.30%), Nucynta IR (19.08%), Nucynta ER (14.58%), and Symproic (2.91%).
Quarterly Revenue by Product
| Product/Service | Mar 24 | Dec 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nucynta ER | $19.19M | $42.35M | $19.17M | $21.14M | $18.95M | $17.13M | $17.08M | $19.26M | $8.73M | - | - | - | - | - | - | - | - | - | - | - |
| Xtampza ER | $45.81M | $88.26M | $41.24M | $47.87M | $35.24M | $38.86M | $33.19M | $31.52M | - | - | - | - | - | - | - | - | - | - | - | - |
| Symproic | $3.30M | $9.01M | $3.84M | $3.65M | $4.53M | $3.58M | $3.86M | $300.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Nucynta IR | $25.96M | $52.09M | $28.16M | $27.90M | $28.89M | $27.27M | $26.55M | $29.34M | $13.37M | - | - | - | - | - | - | - | - | - | - | - |
| Belbuca | $50.66M | $94.75M | $43.14M | $44.21M | $42.05M | $38.80M | $42.30M | $3.31M | - | - | - | - | - | - | - | - | - | - | - | - |
| Other | - | - | - | - | $320.00K | $1.15M | $458.00K | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Elyxyb | - | - | - | - | - | $218.00K | $109.00K | $25.00K | - | - | - | - | - | - | - | - | - | - | - | - |
| Xtampza | - | - | - | - | - | - | - | - | - | $30.02M | $33.02M | $35.41M | $30.79M | $32.13M | $33.56M | $31.51M | $26.48M | $26.02M | $25.13M | $17.03M |
| Nucynta Er | - | - | - | - | - | - | - | - | - | $19.74M | $20.68M | $21.79M | $16.20M | $17.05M | $15.43M | $17.03M | - | - | - | - |
| Nucynta Ir | - | - | - | - | - | - | - | - | - | $29.09M | $29.24M | $30.53M | $29.27M | $30.00M | $29.07M | $27.97M | - | - | - | - |
| Nucynta | - | - | - | - | - | - | - | - | - | $48.83M | $49.92M | $52.31M | $45.48M | $47.05M | $44.50M | $45.00M | $46.46M | $49.02M | $49.38M | $53.14M |
Collegium Pharmaceutical's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Belbuca (34.96%), Xtampza ER (31.61%), Nucynta IR (17.91%), Nucynta ER (13.24%), and Symproic (2.28%).
Collegium Pharmaceutical Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RDY | Dr. Reddy's Laboratories | $279.16B | - |
| ALKS | Alkermes | $1.66B | $378.14M |
| PBH | Prestige Consumer Healthcare | $1.13B | $267.14M |
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| PCRX | Pacira BioSciences | $674.98M | $178.02M |
| AMPH | Amphastar Pharmaceuticals | $593.24M | $182.39M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| ITCI | Intra-Cellular Therapies | $462.18M | $175.38M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| EOLS | Evolus | $199.72M | $66.22M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| RGC | Regencell Bioscience | - | - |
COLL Revenue FAQ
What is Collegium Pharmaceutical’s yearly revenue?
Collegium Pharmaceutical's yearly revenue for 2023 was $566.77M, representing an increase of 22.17% compared to 2022. The company's yearly revenue for 2022 was $463.93M, representing an increase of 67.56% compared to 2021. COLL's yearly revenue for 2021 was $276.87M, representing a decrease of -10.69% compared to 2020.
What is Collegium Pharmaceutical’s quarterly revenue?
Collegium Pharmaceutical's quarterly revenue for Q1 2024 was $144.92M, a -3.22% decrease from the previous quarter (Q4 2023), and a 0.11% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $149.74M, a 9.54% increase from the previous quarter (Q3 2023), and a 15.53% increase year-over-year (Q4 2022). COLL's quarterly revenue for Q3 2023 was $136.71M, a 0.86% increase from the previous quarter (Q2 2023), and a 7.63% increase year-over-year (Q3 2022).
What is Collegium Pharmaceutical’s revenue growth rate?
Collegium Pharmaceutical's revenue growth rate for the last 3 years (2021-2023) was 104.71%, and for the last 5 years (2019-2023) was 91.02%.
What are Collegium Pharmaceutical’s revenue streams?
Collegium Pharmaceutical's revenue streams in c 23 are Nucynta IR, Symproic, Xtampza ER, Belbuca, and Nucynta ER. Nucynta IR generated $108.15M in revenue, accounting 19.08% of the company's total revenue, down -3.49% year-over-year. Symproic generated $16.5M in revenue, accounting 2.91% of the company's total revenue, up 34.47% year-over-year. Xtampza ER generated $177.37M in revenue, accounting 31.30% of the company's total revenue, up 27.79% year-over-year. Belbuca generated $182.1M in revenue, accounting 32.13% of the company's total revenue, up 43.99% year-over-year. Nucynta ER generated $82.65M in revenue, accounting 14.58% of the company's total revenue, up 14.13% year-over-year.
What is Collegium Pharmaceutical’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Collegium Pharmaceutical was Belbuca. This segment made a revenue of $182.1M, representing 32.13% of the company's total revenue.